Enzomend Tablet is a pharmaceutical formulation combining Bromelain (90mg), Trypsin (48mg), and Rutoside (100mg), designed to provide anti-inflammatory, proteolytic, and vascular protective effects. Bromelain, a proteolytic enzyme derived from pineapple stems, facilitates the breakdown of proteins, thereby reducing inflammation and edema associated with trauma, surgery, or chronic inflammatory conditions. Trypsin, another proteolytic enzyme, complements Bromelain by enhancing the degradation of fibrin and promoting the resolution of inflammatory exudates, which aids in tissue repair and accelerates healing processes. Rutoside, a bioflavonoid, exerts antioxidant properties and strengthens capillary walls, reducing capillary permeability and fragility, which is beneficial in managing conditions involving microvascular insufficiency and venous disorders. The synergistic action of these components makes Enzomend Tablet effective in the management of acute and chronic inflammatory states, postoperative swelling, sports injuries, and vascular complications such as varicose veins and hemorrhoids. It is indicated for patients requiring adjunctive therapy to reduce pain, swelling, and promote faster recovery. Enzomend should be administered under medical supervision, with dosage tailored to individual clinical needs, and is contraindicated in patients with hypersensitivity to any of its constituents or active bleeding disorders.